Taiwanese people with familial amyloid polyneuropathy (FAP) have a significantly altered composition of intestinal bacteria relative to their unrelated healthy family members, a new study showed. In addition, the composition of gut microbiota, or bacteria living in the intestines, was associated not only with the severity of nerve damage…
Getting genetic counseling can encourage people at risk for hereditary transthyretin amyloidosis to have genetic testing and know they have the option to seek early treatment if needed, a study suggests. Hereditary transthyretin amyloidosis is a group of diseases that include familial amyloid polyneuropathy (FAP). Having genetic testing can…
Rising levels of a protein called neurofilament light chain (NfL) in the blood may indicate nerve damage due to familial amyloid polyneuropathy (FAP) even before the disease manifests, a study in 65 people reports. These findings suggest that testing for NfL levels could be used to detect nerve damage…
Wainua (eplontersen) is able to slow disease progression and improve life quality for people with familial amyloid polyneuropathy (FAP) regardless of nutritional status, sex, or certain genetic factors. That’s according to new subgroup analyses from the Phase 3 NEURO-TTRansform clinical trial (NCT04136184), whose top-line data supported Wainua’s…
A new mutation in the TTR gene was identified as the cause of late-onset familial amyloid polyneuropathy (FAP) in an elderly man in Argentina, a small case study indicates. The case highlights “the importance of including FAP-TTR among early differential diagnosis in patients with presumably idiopathic [of uncertain cause]…
Tegsedi (inotersen) safely and effectively slowed the progression of polyneuropathy, or damage to multiple nerves, when taken for up to about six years for 10 adults with familial amyloid polyneuropathy (FAP) in Brazil, according to a real-world study. While the data add to results of Tegsedi clinical trials,…
Four years of treatment with Onpattro (patisiran) safely prevents disease progression for most familial amyloid polyneuropathy (FAP) patients, according to a retrospective real-world study in Italy. “These data are not very different from those obtained in the APOLLO trial,” which supported the therapy’s approvals worldwide, the researchers wrote. The…
Among familial amyloid polyneuropathy (FAP) patients carrying the most common FAP-causing mutation Val30Met, treatment with tafamidis meglumine is most effective when given at the very early stages of the disease. That’s according to the findings of a real-world study in Spain, which linked a cutoff value of 15 or…
A noninvasive test that measures axonal excitability, or the processes that underlie electrical impulses along nerve fibers, could distinguish between the early and later stages of familial amyloid polyneuropathy (FAP), a study reports. “Axonal excitability has utility to identify early and progressive nerve dysfunction in [FAP],” the researchers wrote…
Treatment with Amvuttra (vutrisiran) may ease heart damage in people with familial amyloid polyneuropathy (FAP), a new analysis of the HELIOS-A Phase 3 clinical trial suggests. “The totality of assessments in this exploratory analysis of the HELIOS-A study provides evidence of potential benefit of [Amvuttra] on cardiac [heart-related] manifestations…